Merrill: Confidence...
Health Care: Drugs
Repros Therapeutics Inc. (RPRX: NASDAQ)
$15.62 -0.12 | -0.75%
05/21/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 24.21M | 4.56M | 2.96M | 1.89M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 24.62M | 4.66M | 3.28M | 2.06M |
| Property, Plant & Equipment, Gross | 154.00K | 123.00K | 109.00K | 102.00K |
| Accumulated Depreciation & Depletion | 101.00K | 108.00K | 102.00K | 90.00K |
| Property, Plant & Equipment, Net | 53.00K | 15.00K | 7.00K | 12.00K |
| Intangibles | 0.00 | 0.00 | 0.00 | 885.00K |
| Other Non-Current Assets | 2.16M | 1.38M | 1.17M | 0.00 |
| Total Non-Current Assets | 2.21M | 1.40M | 1.18M | 897.00K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 26.83M | 6.06M | 4.46M | 2.96M |
| Accounts Payable | 3.24M | 1.14M | 1.15M | 2.04M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 3.80M | 1.40M | 1.30M | 2.40M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.80M | 1.40M | 1.30M | 2.40M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 23.03M | 4.67M | 3.17M | 562.00K |
| Common Par | 17.00K | 12.00K | 9.00K | 26.00K |
| Additional Paid In Capital | 234.30M | 197.77M | 183.78M | 176.39M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -209.90M | -191.74M | -179.24M | -174.48M |
| Treasury Stock | -1.38M | -1.38M | -1.38M | -1.38M |
| Other Equity Adjustments | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Capitalization | 23.03M | 4.67M | 3.17M | 562.00K |
| Total Equity | 23.03M | 4.67M | 3.17M | 562.00K |
| Total Liabilities & Stock Equity | 26.83M | 6.06M | 4.46M | 2.96M |
| Total Common Shares Outstanding | 17.16M | 12.36M | 8.93M | 6.38M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 112.35K | 112.35K | 112.35K | 112.35K |
| Basic Weighted Shares Outstanding | 15.35M | 11.96M | 8.06M | 4.34M |
| Diluted Weighted Shares Outstanding | 15.35M | 11.96M | 8.06M | 4.34M |
| Number of Employees | 21 | 13 | 6 | 5 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with RPRX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Cheap Biotech Stocks Tha...
- Contributor16 Small-Cap Stocks in Dang...
- ContributorUnder $5 Stocks at Risk of ...
- UserSUPRATRADE Top Day Trader A...
- UserMicrobanks
Latest RPRX Headlines from TheStreet
- Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results 05.10.13 | 09:05 am
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin 05.10.13 | 07:05 am
- Repros Patent Problems Began When Harry Met Joe 05.09.13 | 08:05 am
- Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead Of Schedule 05.02.13 | 12:05 pm
- Repros' Proellex(R) In Breast Cancer Phase 2 Study In Collaboration With Northwestern University 04.29.13 | 12:04 pm
- Repros To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference 04.29.13 | 11:04 am
- Repros Reports Issuance Of Two Additional U.S. Androxal(R) Patents 04.10.13 | 12:04 pm
- The Five Dumbest Things on Wall Street: April 5
04.05.13 | 06:04 am - Repros CEO: My Testosterone Drug Helped Gay Cubans Have Lots of Sex 03.28.13 | 12:03 pm
- Repros Reports Both Primary Endpoints Successfully Met In First Pivotal Study Of Androxal(R) 03.27.13 | 08:03 pm
Press Releases for RPRX
- Repros® Announces Dismissal Of Class Action Lawsuits - Business Wire 03.03.11 | 05:03 pm
- Repros Therapeutics® Announces Pricing Of Public Offering Of Common Stock And Warrants - Business Wire 02.03.11 | 03:02 pm
- Repros Therapeutics® Receives IRB Approval To Commence Phase IIb Study Of Androxal® In The Treatment Of Secondary Hypogonadism - Business Wire 01.03.11 | 09:01 am
- Reanalysis By Outside Statistician Shows Androxal® Provides Statistically Significant Improvement In Testosterone Levels In Men With Male Hormone Levels ≤ 250 Ng/dL - Business Wire 12.28.10 | 09:12 am
- Vaginal Delivery Of Repros’® Proellex® Bypasses First Pass Liver Effects And Achieves Greater Signals Of Efficacy At Significantly Lower Exposure - Business Wire 12.27.10 | 09:12 am
- Repros® Therapeutics Submits Data To The FDA Supporting Morning Assessment Of Testosterone For Men Treated With Androxal® As Indicative Of Average And Maximum Levels Attained - Business Wire 12.23.10 | 11:12 am
- Repros® Therapeutics Prepares To Commence Dosing In Second Cohort In Low Dose Proellex® Study - Business Wire 12.16.10 | 12:12 pm
- Repros Therapeutics Inc.® Reports Third Quarter 2010 Financial Results And Provides Corporate Update - Business Wire 11.10.10 | 06:11 am
- Repros® Announces Reverse Stock Split Effective On Nasdaq October 15, 2010 - Business Wire 10.14.10 | 08:10 pm
- FDA Grants Type B Meeting To Be Held November 8, 2010 To Discuss Phase III Protocols For Androxal® - Business Wire 09.30.10 | 06:09 am
Partner Headlines for RPRX
- Analysts: BlackBerry Rates Were Unimpressive and 4 New Opinions Investors Must Read Now - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Analysts: BlackBerry Rates Were Unimpressive and 4 New Opinions Investors Must Read Now - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Insiders Love These 3 Highly Shorted Healthcare Stocks - Seeking Alpha 01.23.13 | 09:01 am
- A Pullback Would Be Healthy For Repros Therapeutics - Seeking Alpha 09.20.12 | 09:09 am
- Update on Repros' Androxal - Analyst Blog - NASDAQ 09.14.12 | 09:09 pm
- Update on Repros' Androxal - Analyst Blog - Zacks 09.14.12 | 06:09 pm
- Earnings Miss at Repros - Analyst Blog - NASDAQ 08.17.12 | 06:08 pm
- A Closer Look At Repros Therapeutics - Seeking Alpha 07.29.12 | 07:07 am
- Four Biotechs to Watch Early This Week - Seeking Alpha 03.06.11 | 08:03 am
- UPDATE 1-Repros submits more testosterone drug data, shrs soar - Reuters 12.23.10 | 01:12 pm
